|
Note 14 - License Agreements (Details)
In Millions, unless otherwise specified |
12 Months Ended | 12 Months Ended | 132 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
Regulatory Approvals [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
Gross Sale Targets [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
Minimum [Member]
UVIC Industry Partnerships Inc. [Member]
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
Maximum [Member]
UVIC Industry Partnerships Inc. [Member]
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Benign Prostate Hyperplasia [Member]
UVIC Industry Partnerships Inc. [Member]
CAD
|
Dec. 31, 2013
Benign Prostate Hyperplasia [Member]
USD ($)
|
Dec. 31, 2014
Prostate Cancer [Member]
Regulatory Approvals [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostate Cancer [Member]
Gross Sale Targets [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostate Cancer [Member]
Development Activities [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostate Cancer [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2004
Prostate Cancer [Member]
UVIC Industry Partnerships Inc. [Member]
CAD
|
Dec. 31, 2014
Prostate Cancer [Member]
UVIC Industry Partnerships Inc. [Member]
CAD
|
Dec. 31, 2014
Prostatitis and other Diseases of Prostate [Member]
Regulatory Approvals [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostatitis and other Diseases of Prostate [Member]
Gross Sale Targets [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostatitis and other Diseases of Prostate [Member]
Development Activities [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Prostatitis and other Diseases of Prostate [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Milestones not Associated with Indication [Member]
Regulatory Approvals [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Milestones not Associated with Indication [Member]
Gross Sale Targets [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Milestones not Associated with Indication [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Minimum [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
|
Dec. 31, 2014
Maximum [Member]
Kissei Pharmaceuticals Co. Ltd. [Member]
|
Apr. 30, 2010
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2014
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
Dec. 31, 2013
Kissei Pharmaceuticals Co. Ltd. [Member]
USD ($)
|
|
| Note 14 - License Agreements (Details) [Line Items] | ||||||||||||||||||||||||||
| Upfront Payment Related to Licensing Agreement | $ 3.0 | |||||||||||||||||||||||||
| Revenue Recognition, Milestone Method, Revenue Recognized | 5.0 | 5.0 | ||||||||||||||||||||||||
| Non Refundable Milestone Payments Entitled to Receive | 7.0 | 5.0 | 12.0 | 7.0 | 7.0 | 7.0 | 21.0 | 7.0 | 7.0 | 7.0 | 21.0 | 5.0 | 8.0 | 13.0 | 67.0 | |||||||||||
| Percentage of Royalty Payable under Agreement | 20.00% | 29.00% | ||||||||||||||||||||||||
| Payments under License Agreements (in Dollars) | 1.3 | 3.6 | ||||||||||||||||||||||||
| Percentage Of Consideration In Cash | 10.00% | 19.00% | ||||||||||||||||||||||||
| Percentage of Consideration in Cash Reduced | 25.00% | |||||||||||||||||||||||||
| Milestone Payments | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||||
| Accrued Royalties | 0.4 | |||||||||||||||||||||||||
| License Costs | $ 0.6 | |||||||||||||||||||||||||